To report a case of advanced metastatic clear cell sarcoma (CCS) and the treatment outcomes with cadonilimab, highlighting the rarity and aggressiveness of CCS.
Key Findings:
The patient achieved a progression-free survival of more than 24 months with cadonilimab.
This outcome is descriptively better compared to previously reported benchmarks for CCS.
The specific contribution of cadonilimab is uncertain due to the combined treatment strategy.
Interpretation:
The results should be interpreted cautiously due to the single-case nature of the study and the combination of therapies used.
Limitations:
Single-case report limits generalizability.
Combined treatment strategy complicates the assessment of cadonilimab's specific efficacy.
Conclusion:
Further studies are needed to validate these findings regarding cadonilimab in advanced CCS.
